TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2

Key Points

• Olaparib shows significant activity in metastatic breast cancer patients with germline PALB2 mutations and somatic BRCA mutations.
• The study identifies a greater population of breast cancer patients likely to benefit from PARP inhibitors, specifically beyond BRCA1 and BRCA2 carriers.
• Patients with PALB2 or BRCA mutations exhibit enhanced responses, implying that treatment can be expanded for those typically excluded.
• This research supports developing targeted therapies aimed at broader genetic profiles in cancer management.